Bayer Navigates Pivotal Weeks: FDA Priority Review Meets Supreme Court Decision Countdown

Bayer awaits a critical Supreme Court decision on June 18 while its drug pipeline gains momentum with Asundexian and AskBio gene therapy, creating a tense risk-reward balance.

Investors in Bayer are bracing for a binary event on June 18, when the US Supreme Court is expected to hand down its ruling in the long-running glyphosate litigation. That date now dominates the near-term outlook for the stock, but the company’s pipeline has quietly been generating its own positive headlines — creating a tense standoff between legal risk and pharmaceutical potential.

The Supreme Court will decide on the “Durnell” case, a bellwether for thousands of similar claims. Berenberg analyst Sebastian Bray assigns a 60% probability of a favourable outcome for Bayer, a view the German private bank has backed by nudging its price target from €40.00 to €40.50 while keeping a “Hold” rating. The market is treating the verdict as a coin flip, and with the stock trading at €36.13 — barely 0.4% above its 200-day moving average of €35.99 — there is little room for error.

On the operational front, Bayer delivered a mixed set of first-quarter numbers. Currency-adjusted group revenue rose to €13.4 billion, while operating profit climbed 9%. Yet free cash flow swung deeply negative to minus €2.3 billion, dragged down by payments for legal settlements. That cash drain remains the most persistent drag on the company’s financial profile.

The management team is also reshaping itself ahead of the court date. In the consumer health division, four new top executives have been appointed: Samantha Avivi takes charge of global marketing, Analia de la Fuente will lead data analytics, and David Tomasi assumes responsibility for worldwide sales. Meanwhile, Dr. Jost Reinhard, formerly head of investor relations, will become the new leader of the radiology unit on August 1, reporting directly to pharma board member Stefan Oelrich.

Away from the legal and organisational turmoil, Bayer’s drug pipeline is generating genuine momentum. In May 2026, the FDA accepted a new drug application for Asundexian, an oral Factor XIa inhibitor designed to prevent secondary strokes. The regulator granted priority review, backed by the pivotal Phase III OCEANIC-STROKE trial, which hit both its primary efficacy and safety endpoints. If approved, Asundexian would become the first FXIa inhibitor approved for secondary stroke prevention globally. China has also awarded priority review, and a filing is under way in Japan — underscoring the product’s blockbuster potential in one of the largest neurological therapy markets.

Less visible but equally significant is AskBio, Bayer’s gene therapy subsidiary. In May 2026, the unit dosed its first patient in a Phase 1/2 trial for AB-1009, targeting late-onset Pompe disease. The therapy has already secured FDA fast-track and orphan drug designations. Current enzyme replacement therapies require lifelong infusions and lose effectiveness over time, meaning a one-time gene therapy could fundamentally reshape that market — and retroactively justify the multi-billion-euro AskBio acquisition.

The structural overhaul is also gaining traction. Bayer has eliminated six layers of management and cut management positions by two-thirds. Cost savings of €700 million were achieved in 2024, followed by €800 million in 2025, with a target of €2 billion in sustainable organisational savings by the end of 2026. At the Pharma Media Day earlier this year, management reiterated plans to return to mid-single-digit growth from 2027 and expand the margin towards 30% by 2030.

From a chart perspective, the stock remains in a technical no-man’s land. The recent cross above the 200-day moving average in early June was interpreted as a bullish signal, but the gap to the 50-day average is still around 5%. The relative strength index sits at 45.7, indicating no extreme positioning. Annualised 30-day volatility of over 31% underscores how jittery the market is.

Ultimately, Bayer is being pulled in two directions. The Supreme Court decision could remove — or deepen — the legal overhang that has kept a lid on the share price. At the same time, the pipeline is producing exactly the kind of catalysts that long-term investors have been waiting for. The coming weeks will test whether the market is ready to look past the courtroom and focus on the science.